In countries where both abemaciclib and ribociclib are available, choosing between them is challenging.

Yuhei YAMAGUCHI· @yymgcmd · X·2026-10-23 22:22· 2 days agoScore45

Body

In countries where both abemaciclib and ribociclib are available, choosing between them is challenging.
In Japan, the recent expansion of adjuvant abemaciclib to monarchE cohort 2 has somewhat narrowed the gap in eligible populations.
#ESMO26

129 views · 2 likes · 0 reposts · 0 replies

Conference abstracts

1ROmatched by Rapid oral 1: Breast cancer, advanced stage

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

4498PNCT03155997 NCT03155997 NCT03155997matched by Translational research and biomarkers

Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE

https://esmocongress.esmo.org

引用@

Maintained iDFS benefit (Δ 5.3%) and favorable OS (Δ 2.1%) with adjuvant ribociclib after 6 years of follow up (all patients off ribo). Efficacy comparable to abema (monarchE), with different toxicity profile and wider population (N+ and high-risk N0). #ESMO26 #ESMOAmbassadors

在 X 查看被引用的帖子

Source: Yuhei YAMAGUCHI · x.com